

## Results of Annual General Meeting

**Neurotech International Limited (ASX: NTI)** ("Neurotech" or "the Company") today held an Annual General Meeting of Members at the offices of BDO Australia - Melbourne, Collins Square, Tower 4, Level 18, 727 Collins St, Docklands VIC 3008.

All resolutions were determined by a poll.

The outcome of each resolution put to shareholders at the Annual General Meeting is set out in the Annexure which accompanies this release.

### Authority

This announcement has been authorised for release by Alessandra Gauvin, Joint Company Secretary.

### Investors:

Dr Thomas Duthy  
Executive Director

[td@neurotechinternational.com](mailto:td@neurotechinternational.com)

+61 (0)402 493 727

### About Neurotech

**Neurotech International Limited (ASX:NTI)** is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

# Disclosure of Proxy Votes

## Neurotech International Limited

Annual General Meeting  
Wednesday, 20 November 2024



**AUTOMIC**  
Automic  
GPO Box 5193, Sydney, NSW 2001  
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)  
F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)  
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 ADOPTION OF REMUNERATION REPORT	P	86,679,187	84,307,813 97.26%	2,276,078 2.63%	31,801,798	95,296 0.11%	84,403,109 97.37%	2,276,078 2.63%	31,801,798	-
2 ELECTION OF ROBERT MAXWELL JOHNSTON	P	135,515,489	98,372,339 72.59%	119,346 0.09%	230,949	37,023,804 27.32%	136,229,476 99.91%	119,346 0.09%	230,949	Carried
3 RE-ELECTION OF GERALD QUIGLEY	P	135,515,489	98,447,339 72.65%	119,346 0.09%	230,949	36,948,804 27.27%	136,229,476 99.91%	119,346 0.09%	230,949	Carried
4 APPROVAL OF 7.1A MANDATE	P	135,656,438	97,200,794 71.65%	1,506,840 1.11%	90,000	36,948,804 27.24%	134,982,931 98.90%	1,506,840 1.10%	90,000	Carried
5 APPROVAL TO ISSUE SECURITIES TO UNRELATED PARTIES UNDER AN INCENTIVE PLAN	-	Resolution withdrawn								
6 CONFIRMATION OF APPOINTMENT OF AUDITOR	P	135,671,438	98,622,634 72.69%	100,000 0.07%	75,000	36,948,804 27.23%	136,404,771 99.93%	100,000 0.07%	75,000	Carried

